Cure8 news brief
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with moderate-to-severe Crohn’s disease and ulcerative colitis.
Regulatory review by FDA and EMA is a key step toward availability.
Adults with moderately to severely active Crohn’s disease or ulcerative colitis; patients currently treated with vedolizumab/Entyvio or considering biologic therapy; clinicians who prescribe biologics; payers and patient advocacy groups focused on access and affordability.
FDA and EMA have accepted for review a Biologics License Application and Marketing Authorisation Application for PB016, a proposed vedolizumab biosimilar to Takeda’s Entyvio, intended for IV treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.
The announcement is a company press release describing completed Phase 1 and a Phase 3 study (NCT05771155) and notes commercial partnership with Fresenius Kabi. This brief summarizes the regulatory milestone reported in the company press release and does not evaluate safety, efficacy, or regulatory decisions.
It is based on the press release and linked clinicaltrial record referenced in the article.
This is a company press release announcing regulatory submissions accepted for review; acceptance for review is not the same as approval. The company's statement references Phase 1 and Phase 3 studies but the press release does not present trial results.
Watch for formal regulatory decisions and peer-reviewed data from the cited trials before drawing conclusions about interchangeability, cost, or clinical equivalence.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
